Advertisement

Glomerular Diseases Associated with Hepatitis B and C Infection, Pediatric

  • Elizabeth Brown
Living reference work entry

Abstract

The hepatitis B (HBV) and C (HCV) viruses infect billions of people worldwide causing chronic infection in hundreds of millions with high morbidity and mortality. Chronic infection with these viruses is a major cause of hepatitis, cirrhosis, and liver failure in adults throughout the world. HBV and HCV are blood-borne virus transmitted by exposure to infected blood and body fluids. Most children acquire these infections in utero or the perinatal period although the increasing use of IV drugs appears to be leading to a surge in adolescent rates of infection. In addition to liver involvement, HBV and HCV can cause extra-hepatic disease including various forms of glomerulonephritis and vasculitis resulting in proteinuria, hypertension, nephrotic syndrome, and end-stage renal disease. Children with HBV most commonly develop membranous nephropathy with clinical manifestations of proteinuria, hypoalbuminemia, and edema. HBV-associated renal disease has been reported to resolve spontaneously in some pediatric patients, but others may benefit from antiviral therapy. HCV-associated renal disease, most commonly seen as cryoglobulinemia and membranoproliferative glomerulonephritis, is rare in the pediatric population but should be considered and evaluated in high-risk patients. The prognosis, long-term sequelae, and treatment recommendations of both HBV and HCV infection are changing rapidly given recent advances in antiviral therapy. Children with chronic HBV and HCV are often not treated unless they manifest overt hepatitis or glomerulonephritis because they are unlikely to have clinically apparent disease until adulthood. Routine vaccination against HBV has decreased the rate of infection and associated disease manifestations substantially. Antiviral therapy in HBV in children is still dependent on interferon-alpha which has significant side effects and is poorly tolerated; however, new medications have been approved for use in adults and will likely change pediatric treatment recommendations in the future as well. Treatment and prognosis of HCV has changed dramatically with the approval of direct acting antiviral (DAAs) in adolescents and adults that can eradicate the virus in some patients with 3 months of treatment. DAAs are often used in combination and recommendations about optimal therapy continue to change frequently. There are ongoing trials to evaluate DAAs in children. Recommendations for when to treat children with HBV and HCV are likely to continue to evolve with the results of current and future clinical trials testing the newer more effective and tolerable antiviral medications.

Keywords

Hepatitis B Hepatitis C Membranoproliferative glomerulonephritis Membranous nephritis Viral-associated glomerulonephritis 

References

  1. Southwest Pediatric Nephrology Study Group (1985) Hepatitis B surface antigenemia in North American children with membranous glomerulonephropathy. J Pediatr 106:571–578Google Scholar
  2. Abara WE, Qaseem A, Schillie S, McMahon BJ, Harris AM, High Value Care Task Force of the American College of Physicians and the Centers for Disease Control and Prevention (2017) Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med 167:794–804CrossRefGoogle Scholar
  3. Asinobi AO, Ademola AD, Okolo CA, Adepoju AA, Samuel SM, Hoy WE (2018) Kidney disease in hepatitis B surface antigen-positive children: experience from a centre in south-west Nigeria and a review of the Nigerian literature. Paediatr Int Child Health 38:16–22CrossRefGoogle Scholar
  4. Asrani SK, Buchanan P, Pinsky B, Rey LR, Schnitzler M, Kanwal F (2010) Lack of association between hepatitis C infection and chronic kidney disease. Clin Gastroenterol Hepatol 8:79–84CrossRefGoogle Scholar
  5. Balistreri WF, Murray KF, Rosenthal P, Bansal S, Lin CH, Kersey K, Massetto B, Zhu Y, Kanwar B, German P, Svarovskaia E, Brainard DM, Wen J, Gonzalez-Peralta RP, Jonas MM, Schwarz K (2017) The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. Hepatology 66:371–378CrossRefGoogle Scholar
  6. Barritt AST, Lee B, Runge T, Schmidt M, Jhaveri R (2018) Increasing prevalence of hepatitis C among hospitalized children is associated with an increase in substance abuse. J Pediatr 192:159–164CrossRefGoogle Scholar
  7. Cacoub P, Desbois AC, Isnard-Bagnis C, Rocatello D, Ferri C (2016) Hepatitis C virus infection and chronic kidney disease: time for reappraisal. J Hepatol 65:S82–S94CrossRefGoogle Scholar
  8. Centers for Disease Control and Prevention (2015) Viral hepatitis statistics and surveillance: disease burden from viral hepatitis A, B, and C in the United States [Online]. Available https://www.cdc.gov/hepatitis/statistics/index.htm. Accessed 1 Mar 2018
  9. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359–362CrossRefGoogle Scholar
  10. Combes B, Shorey J, Barrera A, Stastny P, Eigenbrodt EH, Hull AR, Carter NW (1971) Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet 2:234–237CrossRefGoogle Scholar
  11. Eleftheriou D, Dillon MJ, Tullus K, Marks SD, Pilkington CA, Roebuck DJ, Klein NJ, Brogan PA (2013) Systemic polyarteritis nodosa in the young: a single-center experience over thirty-two years. Arthritis Rheum 65:2476–2485CrossRefGoogle Scholar
  12. Elewa U, Sandri AM, Kim WR, Fervenza FC (2011) Treatment of hepatitis B virus-associated nephropathy. Nephron Clin Pract 119:c41–c49; discussion c49CrossRefGoogle Scholar
  13. Elidrissy AT, Abdurrahman MB, Ramia S, Lynch JB (1988) Hepatitis B surface antigen associated nephrotic syndrome. Ann Trop Paediatr 8:157–161CrossRefGoogle Scholar
  14. El-Shabrawi MH, Kamal NM (2013) Burden of pediatric hepatitis C. World J Gastroenterol 19:7880–7888CrossRefPubMedCentralGoogle Scholar
  15. Fabrizi F, Plaisier E, Saadoun D, Martin P, Messa P, Cacoub P (2013) Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis 61:623–637CrossRefGoogle Scholar
  16. Ferri C, Giuggioli D, Colaci M (2017) Renal manifestations of hepatitis C virus. Clin Liver Dis 21:487–497CrossRefGoogle Scholar
  17. Garazzino S, Calitri C, Versace A, Alfarano A, Scolfaro C, Bertaina C, Vatrano S, Mignone F, Licciardi F, Gabiano C, Tovo PA (2014) Natural history of vertically acquired HCV infection and associated autoimmune phenomena. Eur J Pediatr 173:1025–1031CrossRefGoogle Scholar
  18. Gilbert RD, Wiggelinkhuizen J (1994) The clinical course of hepatitis B virus-associated nephropathy. Pediatr Nephrol 8:11–14CrossRefGoogle Scholar
  19. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:S45–S57CrossRefGoogle Scholar
  20. Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O, Noel LH, Trepo C (1995) Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 74:238–253CrossRefGoogle Scholar
  21. Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, Cohen P (2005) Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 84:313–322CrossRefGoogle Scholar
  22. Gupta A, Quigg RJ (2015) Glomerular diseases associated with hepatitis B and C. Adv Chronic Kidney Dis 22:343–351CrossRefGoogle Scholar
  23. Houghton M, Weiner A, Han J, Kuo G, Choo QL (1991) Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 14:381–388CrossRefGoogle Scholar
  24. Indolfi G, Bartolini E, Olivito B, Azzari C, Resti M (2012) Autoimmunity and extrahepatic manifestations in treatment-naive children with chronic hepatitis C virus infection. Clin Dev Immunol 2012:785627CrossRefPubMedCentralGoogle Scholar
  25. Jhaveri R, Swamy GK (2014) Hepatitis C virus in pregnancy and early childhood: current understanding and knowledge deficits. J Pediatric Infect Dis Soc 3(Suppl 1):S13-8PubMedGoogle Scholar
  26. Jonas MM, Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Mouchli MA, Singh S, Prokop LJ, Murad MH, Mohammed K (2016) Antiviral therapy in management of chronic hepatitis B viral infection in children: a systematic review and meta-analysis. Hepatology 63:307–318CrossRefGoogle Scholar
  27. Karnsakul W, Schwarz KB (2017) Hepatitis B and C. Pediatr Clin North Am 64:641–658CrossRefPubMedCentralGoogle Scholar
  28. Lai KN, Lai FM, Lo ST, Lam CW (1987) IgA nephropathy and membranous nephropathy associated with hepatitis B surface antigenemia. Hum Pathol 18:411–414CrossRefGoogle Scholar
  29. Lee CK, Jonas MM (2015) Hepatitis C: issues in children. Gastroenterol Clin North Am 44:901–909CrossRefGoogle Scholar
  30. Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, Rosenthal P, Schwarz KB, North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (2012) NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 54:838–855CrossRefGoogle Scholar
  31. Matsumoto S, Nakajima S, Nakamura K, Etani Y, Hirai H, Shimizu N, Yokoyama H, Kobayashi Y, Tajiri H, Shima M, Okada S (2000) Interferon treatment on glomerulonephritis associated with hepatitis C virus. Pediatr Nephrol 15:271–273CrossRefGoogle Scholar
  32. Mendizabal M, Reddy KR (2017) Chronic hepatitis C and chronic kidney disease: advances, limitations and unchartered territories. J Viral Hepat 24:442–453CrossRefGoogle Scholar
  33. Mizuochi T, Takano T, Yanagi T, Ushijima K, Suzuki M, Miyoshi Y, Ito Y, Inui A, Tajiri H (2017) Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan. J Gastroenterol 53(3):419–426CrossRefGoogle Scholar
  34. Morales JM, Kamar N, Rostaing L (2012) Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy. Contrib Nephrol 176:10–23CrossRefGoogle Scholar
  35. Nannini P, Sokal EM (2017) Hepatitis B: changing epidemiology and interventions. Arch Dis Child 102:676–680CrossRefGoogle Scholar
  36. Ozdamar SO, Gucer S, Tinaztepe K (2003) Hepatitis-B virus associated nephropathies: a clinicopathological study in 14 children. Pediatr Nephrol 18:23–28CrossRefGoogle Scholar
  37. Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, Bienvenu B, Mouthon L, Guillevin L (2010) Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 62:616–626CrossRefGoogle Scholar
  38. Park H, Chen C, Wang W, Henry L, Cook RL, Nelson DR (2017) Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. Hepatology.  https://doi.org/10.1002/hep.29505. [Epub ahead of print]CrossRefPubMedCentralGoogle Scholar
  39. Pham YH, Rosenthal P (2016) Chronic hepatitis C infection in children. Adv Pediatr 63:173–194CrossRefGoogle Scholar
  40. Ruebner RL, Reese PP, Denburg MR, Rand EB, Abt PL, Furth SL (2012) Risk factors for end-stage kidney disease after pediatric liver transplantation. Am J Transplant 12:3398–3405CrossRefPubMedCentralGoogle Scholar
  41. Shah AS, Amarapurkar DN (2018) Spectrum of hepatitis B and renal involvement. Liver Int 38:23–32CrossRefGoogle Scholar
  42. Soderholm J, Millbourn C, Busch K, Kovamees J, Schvarcz R, Lindahl K, Bruchfeld A (2018) Higher risk of renal disease in chronic hepatitis C patients: antiviral therapy survival benefit in patients on hemodialysis. J Hepatol 68(5):904–911.  https://doi.org/10.1016/j.jhep.2017.12.003. Epub 2017 Dec 9CrossRefGoogle Scholar
  43. Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F, Kelly D, Mieli-Vergani G, European Society of Pediatric Gastroenterology, Hepatology and Nutrition (2013) Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Hepatol 59:814–829CrossRefGoogle Scholar
  44. Squires JE, Balistreri WF (2017) Hepatitis C virus infection in children and adolescents. Hepatol Commun 1:87–98CrossRefPubMedCentralGoogle Scholar
  45. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, Forouzanfour MH, Groeger J, Hanafiah KM, Jacobsen KH, James SL, MacLachlan J, Malekzadeh R, Martin NK, Mokdad AA, Mokdad AH, Murray CJL, Plass D, Rana S, Rein DB, Richardus JH, Sanabria J, Saylan M, Shahraz S, So S, Vlassov VV, Weiderpass E, Wiersma ST, Younis M, Yu C, El Sayed Zaki M, Cooke GS (2016) The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388:1081–1088CrossRefPubMedCentralGoogle Scholar
  46. Sugiura T, Yamada T, Kimpara Y, Fujita N, Goto K, Koyama N (2009) Effects of pegylated interferon alpha-2a on hepatitis-C-virus-associated glomerulonephritis. Pediatr Nephrol 24:199–202CrossRefGoogle Scholar
  47. Tovo PA, Calitri C, Scolfaro C, Gabiano C, Garazzino S (2016) Vertically acquired hepatitis C virus infection: correlates of transmission and disease progression. World J Gastroenterol 22:1382–1392CrossRefPubMedCentralGoogle Scholar
  48. Venkataseshan VS, Lieberman K, Kim DU, Thung SN, Dikman S, D’Agati V, Susin M, Valderrama E, Gauthier B, Prakash A et al (1990) Hepatitis-B-associated glomerulonephritis: pathology, pathogenesis, and clinical course. Medicine (Baltimore) 69:200–216CrossRefGoogle Scholar
  49. Wirth S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, Balistreri WF, Lin CH, Hardikar W, Kersey K, Massetto B, Kanwar B, Brainard DM, Shao J, Svarovskaia E, Kirby B, Arnon R, Murray KF, Schwarz KB (2017) Sofosbuvir and ribavirin in adolescents 12–17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology 66:1102–1110CrossRefGoogle Scholar
  50. Xu H, Sun L, Zhou LJ, Fang LJ, Sheng FY, Guo YQ (2003) The effect of hepatitis B vaccination on the incidence of childhood HBV-associated nephritis. Pediatr Nephrol 18:1216–1219CrossRefGoogle Scholar
  51. Zhang Y, Li J, Peng W, Yu G, Wang L, Chen J, Zheng F (2016) HBV-associated postinfectious acute glomerulonephritis: a report of 10 cases. PLoS One 11:e0160626CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pediatric NephrologyUT Southwestern Medical CenterDallasUSA

Personalised recommendations